These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038 [TBL] [Abstract][Full Text] [Related]
5. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728 [TBL] [Abstract][Full Text] [Related]
6. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia. Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228 [TBL] [Abstract][Full Text] [Related]
7. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519 [TBL] [Abstract][Full Text] [Related]
8. Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. Podhorecka M; Goracy A; Szymczyk A; Kowal M; Ibanez B; Jankowska-Lecka O; Macheta A; Nowaczynska A; Drab-Urbanek E; Chocholska S; Jawniak D; Hus M Oncotarget; 2017 May; 8(21):34661-34669. PubMed ID: 28416773 [TBL] [Abstract][Full Text] [Related]
9. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Maharaj K; Powers JJ; Achille A; Deng S; Fonseca R; Pabon-Saldana M; Quayle SN; Jones SS; Villagra A; Sotomayor EM; Sahakian E; Pinilla-Ibarz J Blood Adv; 2018 Nov; 2(21):3012-3024. PubMed ID: 30425065 [TBL] [Abstract][Full Text] [Related]
10. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Hing ZA; Mantel R; Beckwith KA; Guinn D; Williams E; Smith LL; Williams K; Johnson AJ; Lehman AM; Byrd JC; Woyach JA; Lapalombella R Blood; 2015 May; 125(20):3128-32. PubMed ID: 25838351 [TBL] [Abstract][Full Text] [Related]
11. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951 [TBL] [Abstract][Full Text] [Related]
13. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626 [TBL] [Abstract][Full Text] [Related]
14. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. Till KJ; Pettitt AR; Slupsky JR J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398 [TBL] [Abstract][Full Text] [Related]
16. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675 [TBL] [Abstract][Full Text] [Related]
17. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. de Rooij MF; Kuil A; Kater AP; Kersten MJ; Pals ST; Spaargaren M Blood; 2015 Apr; 125(14):2306-9. PubMed ID: 25838279 [No Abstract] [Full Text] [Related]